Hepatocellular Carcinoma (HCC), also known as liver cancer, is a severe disease due to its high prevalence and poor prognosis. More than half a million cases are reported annually and the number is estimated to rise as Hepatitis C (HCV) rates of infection and improved clinical management of liver cirrhosis increase. Prognosis depends on the stage of the cancer; less than 3 months in very advanced tumors. The size of a tumor influences directly the possibility of surgical or ablative interventions, and a small tumor has a better chance of being cured.
|An immunohistochemical kit for the detection of Hepatocellular Carcinoma (HCC) from liver biopsies|
|ELISA Kit for the detection of Squamous Cell Carcinoma Antigen variants Immune Complexes (SCCA-IgM)|
|ELISA Kit for the detection of Alpha-Fetoprotein (AFP) Immune Complexes in Hepatocellular Carcinoma (HCC)|
|A new index to identify the risk of developing non-alcoholic steatohepatitis (NASH)|